Additional Listing
June 14, 2016 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company") hereby
notifies the market that an application has been made to the London Stock
Exchange and the UK Listing Authority for a total of 25,000,000 Ordinary shares
of 5 pence each (the "Shares") to trade on the London Stock Exchange and to be
admitted to the Official List. The Shares are to be reserved under a block
listing relating to exchange awards made in accordance with the terms of the
merger agreement pursuant to which the Company combined with Baxalta
Incorporated on June 3, 2016.
When issued, the Shares will rank equally with the existing issued Ordinary
shares of the Company.
Oliver Strawbridge
Senior Assistant Company Secretary
For further information please contact:
Investor Relations
Sarah Elton-Farr seltonfarr@shire.com +44 1256 894157
NOTES TO EDITORS
Shire is the leading global biotechnology company focused on serving people
with rare diseases and other highly specialized conditions. We have
best-in-class products available in more than 100 countries across core
therapeutic areas including Hematology, Immunology, Neuroscience, Lysosomal
Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and
Hereditary Angioedema; a growing franchise in Oncology; and an emerging,
innovative pipeline in Ophthalmics.
Our employees come to work every day with a shared mission: to develop and
deliver breakthrough therapies for the hundreds of millions of people in the
world affected by rare diseases and other high-need conditions, and who lack
effective therapies to live their lives to the fullest.
www.shire.com